Anika Gupta

Anika Gupta Vatsa is a principal at GV, where she focuses on building and investing in biotech companies developing clinically meaningful new medicines. She represents GV on the boards of EpiBiologics and Pretzel Therapeutics.

Prior to GV, she contributed to the formation of several biotech startups and developed bioinformatics frameworks for patient stratification at Foundation Medicine and immunotherapy response prediction at Merck.

Anika earned her Ph.D. in bioinformatics and genomics from Harvard University and the Broad Institute of MIT and Harvard. Her doctoral research with Eric Lander and Soumya Raychaudhuri leveraged single-cell genomics and statistical genetics to define the causal basis of autoimmune diseases, with findings published in Nature Genetics and PNAS.

Anika holds a B.S. in Computer Science and Molecular Biology from MIT, where she co-founded the MIT Biotech Group.